NasdaqGS - Delayed Quote • USD
Dyne Therapeutics, Inc. (DYN)
At close: April 22 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 7 | 6 |
| Avg. Estimate | -0.8 | -0.81 | -3.29 | -3.27 |
| Low Estimate | -0.83 | -0.87 | -3.6 | -4.48 |
| High Estimate | -0.75 | -0.7 | -2.82 | -2.19 |
| Year Ago EPS | -0.78 | -1.08 | -3.95 | -3.29 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 5 | 5 |
| Avg. Estimate | -- | -- | -- | 21.45M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | 105.07M |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.77 | -0.81 | -0.83 | -0.92 |
| EPS Actual | -0.78 | -1.08 | -0.99 | -1.09 |
| Difference | -0.01 | -0.27 | -0.16 | -0.17 |
| Surprise % | -1.30% | -33.30% | -19.30% | -18.50% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.8 | -0.81 | -3.29 | -3.27 |
| 7 Days Ago | -0.8 | -0.81 | -3.29 | -3.27 |
| 30 Days Ago | -0.8 | -0.8 | -3.27 | -3.17 |
| 60 Days Ago | -0.71 | -0.71 | -3.14 | -2.63 |
| 90 Days Ago | -0.68 | -0.68 | -2.85 | -2.52 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | 1 | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | DYN | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -2.60% | -- | -- | 0.20% |
| Next Qtr. | 25.00% | -- | -- | 9.40% |
| Current Year | 16.70% | -- | -- | 4.40% |
| Next Year | 0.60% | -- | -- | 13.40% |
| Next 5 Years (per annum) | -- | -- | -- | 11.07% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Oppenheimer: Outperform to Outperform | 3/26/2024 |
| Maintains | Chardan Capital: Buy to Buy | 3/8/2024 |
| Maintains | Guggenheim: Buy to Buy | 3/7/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/6/2024 |
| Maintains | Stifel: Buy to Buy | 3/6/2024 |
| Maintains | Piper Sandler: Overweight to Overweight | 3/6/2024 |
Related Tickers
RNA Avidity Biosciences, Inc.
24.16
+6.29%
APGE Apogee Therapeutics, Inc.
48.64
+3.69%
SWTX SpringWorks Therapeutics, Inc.
42.89
+6.96%
ACLX Arcellx, Inc.
52.00
+0.68%
MLTX MoonLake Immunotherapeutics
41.02
-2.77%
EWTX Edgewise Therapeutics, Inc.
15.08
-0.98%
MOR MorphoSys AG
17.96
-0.11%
FDMT 4D Molecular Therapeutics, Inc.
26.39
+4.51%
IMCR Immunocore Holdings plc
55.82
+0.25%
IMVT Immunovant, Inc.
28.74
+1.84%